Contraindications: Not for use in individuals with known androgen sensitivity, active or suspected hormone-dependent malignancy, severe hepatic or renal impairment, or uncontrolled cardiovascular disease. Women of childbearing potential should avoid use due to virilisation risk. Do not use if any ampoule shows signs of compromised seal integrity.
Side Effects: Androgenic effects may include increased sebum production, accelerated androgenetic alopecia, and virilisation in female users. Suppression of endogenous testosterone production is expected at standard frontloading doses. Elevated haematocrit, fluid retention, and lipid profile shifts (HDL reduction) have been documented with nandrolone-based compounds in clinical literature.
Monitoring: Haematological panels (haemoglobin, haematocrit, RBC count), lipid profiles, and liver enzyme panels should be assessed at baseline and at weeks 4–6 of an active cycle. Blood pressure monitoring is recommended throughout, particularly during the frontload phase when plasma nandrolone concentrations are at their highest. Injection-site assessment for induration or infection after each loading-phase administration.
PCT: Post-cycle therapy with a SERM (e.g. Tamoxifen or Clomiphene) should begin approximately 5–7 days after the final injection, taking advantage of phenylpropionate's relatively short clearance period. HCG may be incorporated during the final weeks of the cycle to support testicular function recovery prior to SERM initiation.
Fast Acting
